These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 15955619)

  • 1. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
    Swami S; Krishnan AV; Peehl DM; Feldman D
    Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
    Kim S; Shevde NK; Pike JW
    J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH; Zhao XY; Holloway L; Feldman D
    Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
    Hedlund TE; Moffatt KA; Miller GJ
    Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor.
    Dunlop TW; Väisänen S; Frank C; Molnár F; Sinkkonen L; Carlberg C
    J Mol Biol; 2005 Jun; 349(2):248-60. PubMed ID: 15890193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D
    Karlsson S; Diaz Cruz MA; Faresjö M; Khamou AP; Larsson D
    Anticancer Res; 2021 Oct; 41(10):4733-4740. PubMed ID: 34593422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells.
    Farhan H; Wähälä K; Cross HS
    J Steroid Biochem Mol Biol; 2003 Mar; 84(4):423-9. PubMed ID: 12732287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-chaperone potentiation of vitamin D receptor-mediated transactivation: a role for Bcl2-associated athanogene-1 as an intracellular-binding protein for 1,25-dihydroxyvitamin D3.
    Chun RF; Gacad M; Nguyen L; Hewison M; Adams JS
    J Mol Endocrinol; 2007 Aug; 39(2):81-9. PubMed ID: 17693608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D analogues targeting CYP24 in chronic kidney disease.
    Posner GH; Helvig C; Cuerrier D; Collop D; Kharebov A; Ryder K; Epps T; Petkovich M
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):13-9. PubMed ID: 20347976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.
    Munetsuna E; Kawanami R; Nishikawa M; Ikeda S; Nakabayashi S; Yasuda K; Ohta M; Kamakura M; Ikushiro S; Sakaki T
    Mol Cell Endocrinol; 2014 Feb; 382(2):960-70. PubMed ID: 24291609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.
    Reichrath J; Rech M; Moeini M; Meese E; Tilgen W; Seifert M
    Cancer Biol Ther; 2007 Jan; 6(1):48-55. PubMed ID: 17172823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional inhibition of CYP24 by genistein.
    Farhan H; Cross HS
    Ann N Y Acad Sci; 2002 Nov; 973():459-62. PubMed ID: 12485911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
    Osborne JE; Hutchinson PE
    Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of vitamin D receptor regulation for the 1,25-dihydroxyvitamin D3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway.
    Staal A; van den Bemd GJ; Birkenhäger JC; Pols HA; van Leeuwen JP
    Bone; 1997 Mar; 20(3):237-43. PubMed ID: 9071474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
    Yee SW; Campbell MJ; Simons C
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.
    Zhou C; Assem M; Tay JC; Watkins PB; Blumberg B; Schuetz EG; Thummel KE
    J Clin Invest; 2006 Jun; 116(6):1703-12. PubMed ID: 16691293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM; Schwartz GG; Woodruff R; Cramer SD
    Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells.
    Lechner D; Manhardt T; Bajna E; Posner GH; Cross HS
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1119-26. PubMed ID: 17182978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.